Guest Editors
Prof. Filippo Lococo
Email: filippo.lococo@policlinicogemelli.it
Affiliation: Thoracic Surgery Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
Homepage:
Research Interests: NSCLC, translational biology, thymic tumors, mesothelioma
Dr. Emanuele Vita
Email: emanuele.vita@policlinicogemelli.it
Affiliation: Department of Medical Oncology, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy
Homepage:
Research Interests: lung cancer, NSCLC, SCLC
Dr. Luca Boldrini
Email: luca.boldrini@policlinicogemelli.it
Affiliation: Department of Diagnostic Imaging and Radiation Oncology, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy
Homepage:
Research Interests: NSCLC, oligometastases, colorectal cancer
Dr. Edoardo Amante
Email: edoardo.amante@guest.policlinicogemelli.it
Affiliation: Department of Intervention Pneumology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
Homepage:
Research Interests: NSCLC, EBUS, Robot-assisted broncoscopy
Dr. Elisa De Paolis
Email: elisa.depaolis@policlinicogemelli.it
Affiliation: Department of Molecular Biology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
Homepage:
Research Interests: NGS, NSCLC, liquid biopsy
Summary
The management of lung cancer is becoming increasingly complex as detailed knowledge of molecular biology data increases and emerging therapies associated with it evolve. Analysis of the biomolecular pattern in tumor tissue has already partially revolutionized clinical practice in advanced stages, and it is partly thanks to this and to knowledge of the tumor microenvironment that new integrated treatments have been developed in recent years in locally advanced stages and, more recently, even in the earliest stages.
The complexity of decision-making algorithms appears set to grow in the coming years, also thanks to the advent of biomolecular information derived from the blood of lung cancer patients rather than tissue (liquid biopsy).
The aim of this Special Issue will be to explore current knowledge in the molecular biology of lung cancer (tissue biopsy and liquid biopsy) and to assess, in a multidisciplinary manner, the implications that this biological information already has, or will have in the future, on the diagnostic and treatment pathways of lung cancer patients.
We will also aim to foster a better understanding of the potential of AI, which in the future will lead to an increasingly frequent use of early molecular diagnostic tests and personalized treatments "designed" by artificial intelligence algorithms and primarily based on the biological characteristics of each individual tumor.
Keywords
NSCLC, precision medicine, NGS, tissue biopsy, liquid biopsy
Login
Register
Submit a Paper
Propose a Special lssue